STROKEMAP - Multipotent Adult Progenitor Cells to treat Stroke
From 01-10-2006 to 30-09-2009
Description
Successful therapy for stroke will be achieved using cells that can limit ischemic injury and differentiate into the multiple cell types needed for restoring blood flow and neural circuits, and would be available for therapy “off the shelf”. As Multipotent Adult Progenitor Cells (MAPCs) differentiate into vascular and neural cells, and reconstitute damaged tissues in vivo, we hypothesize that MAPCs is an ideal allogeneic cell product to treat stroke.
In WP1 and WP2, we will develop approaches to generate committed vascular cells and neuroprogenitors, and identify key molecular events that guide differentiation.
WPs 3-6 will rigorously evaluate the pre-clinical efficacy of allogeneic MAPCs or their progeny in stroke. This will include development of noninvasive imaging techniques to follow the fate of grafted cells and evaluate their impact on CNS function (WP3). We will compare the efficacy of MAPCs with that of till now “gold-standard” stem cell populations in stroke, and determine mechanisms underlying observed effects (WP4). We will examine the immunogenicity of MAPCs and their differentiated progeny in vitro (WP5) and in vivo using mice with a “human immune system” (WP6).
Studies in WP8 will develop clinical grade culture systems to generate human MAPCs and, if needed, lineage committed progeny. Studies in WP7 will develop a framework in which to develop clinical grade stem cell products in an ethically responsible manner. Specific attention to the management of the project. The management, exploitation and dissemination of the project will be ensured through WP9. These studies will lay the foundation for clinical trials of MAPCs in stroke in Europe in subsequent years. The highly innovative methods, tools and technologies that will be developed will not only be applicable in the area of stem cell based therapies for stroke, but may significantly advance use of human stem cells in regenerative medicine.
Team
- Yves Moreau, Coordinator
- Ernesto Iacucci, Team member
Financing
Funding: EU Funding - European Funding
Program/Grant Type: EU Other - Other
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.